{"groups":[{"description":"Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"FG000","title":"Safety run-in Cohort 1"},{"description":"Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"FG001","title":"Safety run-in Cohort 2"},{"description":"Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"FG002","title":"Safety run-in Cohort 3"},{"description":"Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"FG003","title":"Safety run-in Cohort 4"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The three experimental Arms/Groups: 'Dose Level A in Hodgin Lymphoma', 'Dose Level B in Hodgin Lymphoma' and 'Exploratory: AFM13 + AB-101 on CD30-positive PTCL' were not enrolled due to the decision to terminate this study earlier, which was based solely on the financial situation of the company and was not related to the safety or efficacy."}